Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.from Moneycontrol Business News https://bit.ly/3V08UAJ
via IFTTT
Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma
March 01, 2024
0
Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.from Moneycontrol Business News https://bit.ly/3V08UAJ
via IFTTT
